A Controlled Trial of Renal Denervation for Resistant Hypertension (SYMPLICITY HTN-3)
Source: View publication →
The SYMPLICITY HTN-3 trial was a pivotal, sham-controlled study that failed to demonstrate a significant benefit of radiofrequency renal denervation over a sham procedure in reducing blood pressure in patients with treatment-resistant hypertension at the six-month primary endpoint.
Key Findings
Study Design
Study Limitations
Clinical Significance
The trial fundamentally altered the trajectory of renal denervation as a therapeutic strategy for hypertension, shifting the focus from first-generation devices and broad indications toward more refined procedural techniques and patient selection, ultimately demonstrating that the initial enthusiasm for the procedure was not supported by rigorous, blinded evidence at the 6-month primary assessment.
Historical Context
Following positive results from open-label phase I and II studies (SYMPLICITY HTN-1 and HTN-2), renal denervation was initially met with widespread clinical interest. SYMPLICITY HTN-3 was designed as the rigorous phase III test to secure regulatory approval; its negative efficacy results shocked the medical community and led to a temporary abandonment of the therapy, prompting a complete reassessment of the clinical trial methodology for hypertension devices.
Guided Discussion
High-yield insights from every perspective
What is the physiological rationale for targeting the renal nerves in the treatment of hypertension, and how does the sympathetic nervous system influence the kidney's role in blood pressure regulation?
Key Response
The kidneys are central to blood pressure control through both efferent and afferent sympathetic pathways. Efferent sympathetic activity increases renin secretion, enhances sodium reabsorption, and reduces renal blood flow. Afferent signals from the kidney to the central nervous system increase systemic sympathetic outflow. Ablating these nerves theoretically interrupts this feedback loop, reducing systemic vascular resistance and fluid retention.
In a patient who meets the clinical criteria for resistant hypertension—defined as blood pressure remaining above goal despite three antihypertensive agents including a diuretic—what did the results of SYMPLICITY HTN-3 suggest regarding the immediate role of renal denervation compared to medical therapy?
Key Response
SYMPLICITY HTN-3 was a landmark trial because it was the first large-scale sham-controlled study in this field. It failed to show a statistically significant reduction in systolic blood pressure compared to the sham procedure at six months. For a resident, this means that renal denervation should not be considered a standard-of-care alternative to optimizing pharmacological therapy and addressing lifestyle factors in patients with resistant hypertension.
Earlier unblinded trials (SYMPLICITY HTN-1 and HTN-2) showed dramatic blood pressure reductions, yet HTN-3 was negative. Beyond the 'sham effect,' what technical and pharmacological factors in the SYMPLICITY HTN-3 trial design may have contributed to this discrepancy?
Key Response
Key factors include: 1) Procedural variability, as many operators performed only one or two procedures, leading to potentially incomplete circumferential ablation; 2) Significant changes in background antihypertensive medications during the trial despite the protocol's intent for stability; and 3) Inclusion of patients with isolated systolic hypertension (stiff arteries), who may be less responsive to sympathetic modulation than those with combined systolic/diastolic hypertension.
How did the SYMPLICITY HTN-3 trial change the paradigm of medical device regulation and the level of evidence required for the clinical adoption of interventional therapies for chronic disease?
Key Response
The trial served as a watershed moment, demonstrating that even a biologically plausible and previously 'proven' (in unblinded trials) intervention can fail when subjected to a rigorous sham-controlled RCT. It shifted the field from early enthusiasm to a state of 'evidence-based skepticism,' mandating that future device trials for hypertension utilize sham controls and objective endpoints like 24-hour ambulatory blood pressure monitoring (ABPM).
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critically evaluate the 'failure of the intervention' versus the 'failure of the hypothesis' in SYMPLICITY HTN-3. How would you design a study to validate that renal sympathetic activity was actually reduced in treated subjects, given the lack of an intraprocedural biomarker for successful denervation?
Key Response
The trial's failure may have been a technical failure (incomplete nerve ablation) rather than a flaw in the sympathetic hypothesis. To building on this, research should focus on identifying real-time biomarkers—such as renal norepinephrine spillover or muscle sympathetic nerve activity (MSNA)—to confirm denervation. Without a surrogate marker of procedural success, it remains impossible to distinguish between an ineffective procedure and an unresponsive patient.
As a reviewer for a high-impact journal, why would the discrepancy between office blood pressure and ambulatory blood pressure monitoring (ABPM) in SYMPLICITY HTN-3 be a primary point of concern regarding the study's internal validity?
Key Response
In SYMPLICITY HTN-3, the drop in office systolic blood pressure in the sham group was much larger than expected (-11.7 mmHg). However, the ABPM reductions were more modest. A reviewer would flag this as a 'Hawthorne effect' or 'regression to the mean,' suggesting that office-based measurements were influenced by patient/provider behavior changes rather than the physiological effect of the procedure, thereby making a sham-control arm absolutely essential for a valid conclusion.
Following the SYMPLICITY HTN-3 results, how did major clinical guidelines (such as the ACC/AHA or ESC) adjust the recommendation level for renal denervation, and what specific evidence threshold must be met to reinstate it as a recommended therapy?
Key Response
Post-SYMPLICITY HTN-3, guidelines downgraded renal denervation to 'investigational' or Class III (no benefit) for routine use. To be reconsidered (as seen in more recent 2023/2024 ESH guidelines), the evidence must come from second-generation trials (like SPYRAL HTN or RADIANCE) that utilize more rigorous medication controls and multi-electrode catheters, demonstrating consistent BP reduction across both 'on-med' and 'off-med' cohorts.
Clinical Landscape
Noteworthy Related Trials
SYMPLICITY HTN-2
Tested
Catheter-based renal sympathetic denervation
Population
Patients with resistant hypertension
Comparator
Standard medical therapy
Endpoint
Change in systolic blood pressure at 6 months
SPYRAL HTN-OFF MED
Tested
Renal denervation using a multi-electrode radiofrequency catheter
Population
Patients with uncontrolled hypertension off anti-hypertensive medication
Comparator
Sham procedure
Endpoint
Change in 24-hour ambulatory systolic blood pressure at 3 months
RADIANCE-HTN TRIO
Tested
Ultrasound-based renal denervation
Population
Patients with resistant hypertension on a standardized triple-drug regimen
Comparator
Sham procedure
Endpoint
Change in daytime ambulatory systolic blood pressure at 6 months
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis